Mesoridazine

A to Z Drug Facts

Mesoridazine

 Actions
 Indications
 Contraindications
 Route/Dosage
 Interactions
 Lab Test Interferences
 Adverse Reactions
 Precautions
Patient Care Considerations
 Administration/Storage
 Assessment/Interventions
 Patient/Family Education


(Mez-oh-RID-uh-zeen)
Serentil
Injection: 25 mg/mL
Oral concentrate: 25 mg/mL
Tablets: 10 mg
Tablets: 25 mg
Tablets: 50 mg
Tablets: 100 mg
Class: Antipsychotic
Phenothiazine

 Actions Blocks dopamine receptor in CNS.

 Indications Management of schizophrenia in patients who fail to respond adequately to treatment with other antipsychotic agents.

 Contraindications Congenital QT interval prolongation; concurrent drugs that prolong the QT interval; history of cardiac arrhythmias; severe CNS depression or comatose states (including drug-induced CNS depression); hypersensitivity to mesoridazine.

 Route/Dosage

Because of potentially serious side effects, usethe minimal effective dose.

ADULTS: PO Start with 50 mg tid (optimal dose range, 100 to 400 mg/day).

ADULTS: IM Start with 25 mg and repeat in 30 to 60 min, if necessary (optimal dosage range, 25 to 200 mg/day).

 Interactions

Alcohol and other CNS depressants: May result in increased CNS depression and may precipitate extrapyramidal reaction. Anticholinergics: May reduce therapeutic effects of mesoridazine and worsen anticholinergic effects of mesoridazine. May lead to tardive dyskinesia. Drugs that prolong the QT interval: May increase the risk of life-threatening cardiac arrhythmias (including torsades de pointes).

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Hypotension; prolongation of QTc interval, which is associated with life-threatening cardiac arrhythmias; ventricular arrhythmias; changes in terminal portion of ECG. CNS: Drowsiness; tremor; muscular rigidity; Parkinson syndrome; dizziness; weakness; restlessness; ataxia; slurring; akathisia; fainting; agitation; motor restlessness; dystonic reactions; trismus; torticollis; opisthotonos; oculogyric crises; tardive dyskinesia, bizarre dreams; aggravation of psychoses; toxic confessional state. DERMATOLOGIC: Itching; rash; hypertrophic papilla of tongue; angioneurotic edema; erythema; exfoliative dermatitis; contact dermatitis. EENT: Stuffy nose; photophobia; blurred vision; miosis; tardive dyskinesia; discoloration of sclera and cornea; opacities of the anterior lens and cornea. GI: Dry mouth; nausea; vomiting; constipation; anorexia; paralytic ileus; obstipation. GU: Inhibition of ejaculation; impotence; enuresis; incontinence; priapism; menstrual irregularities; altered libido; gynecomastia; lactation; urinary retention. HEMATOLOGIC: Agranulocytosis; leukopenia; eosinophilia; thrombocytopenia; anemia; aplastic anemia; pancytopenia. HEPATIC: Jaundice; biliary stasis. METABOLIC: Weight gain. OTHER: Fever; laryngeal edema; angioneurotic edema; asthma; edema; hyperpyrexia; systemic lupus erythematosus-like syndrome.

 Precautions

Pregnancy: Safety and efficacy not established. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Neuroleptic malignant syndrome: Has occurred with this class of agents; potentially life-threatening. Signs and symptoms include hyperpyrexia, muscle rigidity, altered mental status, irregular pulse and blood pressure, tachycardia, and diaphoresis. QT interval: The QT and QTc interval are prolonged in a dose-related fashion, which may cause serious ventricular arrhythmias (including torsades de pointes). Tardive dyskinesia: May occur with this class of agents and may become irreversible, depending on the duration of treatment and total cumulative dose. The syndrome consists of involuntary, dyskinetic movements.


PATIENT CARE CONSIDERATIONS


 Administration/Storage

 Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
  Drowsiness, confusion, disorientation, agitation, dry mouth, edema of glottis, laryngeal spasms, nasal congestion, blurred vision, vomiting, hyperpyrexia, dilated pupils, muscle rigidity, hyperactive reflexes, areflexia, stupor, CNS depression or stimulation with convulsions followed by respiratory depression, cardiac abnormalities (including QRS changes), tachycardia, hypotension, bilateral bundle branch block, ventricular fibrillation, shock, cardiac arrest, congenital heart failure, coma, death

 Patient/Family Education

Books@Ovid
Copyright
© 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts